Repligen's Wild Ride: Biopharma Stock Surges, Then Cools
Update: 2025-09-16
Description
Repligen's stock spiked nearly 5% after Stifel reiterated its Buy rating, citing strong bioprocessing momentum driven by Repligen's ATF technology in the booming single-use downstream market. Despite a volatile year and a recent downgrade from another firm, Repligen is positioned to benefit from the growth in monoclonal antibodies, biosimilars, and vaccines. However, investors should also consider the potential of enterprise software companies leveraging trends like generative AI for future growth opportunities.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
